陈兵

文章来源:南京大学医学院发布时间:2019-07-11浏览次数:10

博士研究生导师简介

姓名

陈兵

研究方向

1. 多发性骨髓瘤的基础与临床研究 2. 恶性血液病生物免疫治疗研究

联系方式

Email    chenbing2004@126.com

学术兼职:

中国临床肿瘤学会(CSCO)抗白血病联盟专家委员会常务委员;中国医药教育协会血液专业委员会常务委员;江苏省免疫学会科普工作委员会副主任委员;江苏省医学会血液学分会委员、白血病及感染学组副组长;江苏省抗癌协会血液肿瘤专委会副主任委员;南京医学会血液学分会副主任委员;中国老年医学会血液学分会骨髓瘤学组委员。

个人简介

陈兵,南京大学医学院附属鼓楼医院血液科行政主任,主任医师,医学博士,博士生导师,江苏省十三五科教强卫医学领军人才,江苏省六大高峰人才1995年起在南京鼓楼医院从事血液病临床工作,擅长多发性骨髓瘤、急慢性白血病、骨髓增生异常综合症等的诊治,造血干细胞移植、肿瘤免疫治疗技术2012年作为访问学者赴美国纪念斯隆凯特林癌症中心学习造血干细胞移植及多发性骨髓瘤细胞治疗技术。长期致力于恶性血液系统肿瘤的临床和相关基础研究,在血液系统恶性肿瘤的发病机制、免疫治疗及靶向治疗等方面积累了丰富的理论与临床经验。发表SCI论文二十余篇。多次荣获江苏省新技术引进一等奖、二等奖,江苏省科学技术进步奖三等奖、南京市科技进步三等奖江苏肿瘤医学科学技术奖二等奖等。

代表性论文[5年通讯作者和第一作者]

1Doxorubicin-Loaded PEG-CdTe Quantum Dots as a Smart Drug Delivery System for Extramedullary Multiple Myeloma Treatment. Nanoscale Res Lett .

2018-11.13(1):373.


2Pre-treatment red blood cell distribution width provides prognostic information in multiple myeloma. Clin Chim Acta .2018-0613(1):e0191955.


3Expression of MAGEC1/CT7 provides prognostic information in multiple myeloma.Leukemia & lymphoma .2017-01.58(1):244-246.


4Silencing MAGE-C1/CT7 enhances the anticancer effects of bortezomib in multiple myeloma cell line Int J Clin Exp Med .2016-08.9(8):15124-15134.


5A new strategy for TiO2 whiskers mediated multi-mode cancer treatment. Nanoscale Res Lett. 2015-02.10: 94.


6PEGPLGAPLL nanoparticles in combination with gambogic acid for reversing multidrug resistance of K562/A02 cells to daunorubicin. RSC Advances. 2015-06.

5-61051.


7Anti-CD22-conjugated CdTe QDs co-loaded with doxorubicin and gambogic acid: A novel

platform for lymphoma treatment .RSC advances .2017-07.7(54):33905-33913.


8Prognostic relevance of protein expression,clinical factors, and MYD88 mutation in

primary bone lymphoma Oncotarget.2017-08.8 ( 39):65609-65619.


9Doxorubicin-loaded platelets conjugated with anti-CD22 mAbs: a novel targeted delivery system for lymphoma treatment with cardiopulmonary avoidance. Oncotarget

2017-08.8(35):58322-58337.


10Comparison of outcomes in hematological malignancies treated with haploidentical or HLA-identical sibling hematopoietic stem cell transplantation following myeloablative conditioning: A metaanalysis. PLoS One .2018-01.13(1):e01919 55.


11TP53 mutation predicts the poor prognosis of non-Hodgkin lymphomas: Evidence

from a meta-analysis .PLoS One.2017-04.12(4):e0174809.


12STAT5 gene polymorphisms are associated with the response of acute myeloid leukemia

patients to Ara-C-based chemotherapy.Leukemia & lymphoma.2016-04.57-4-921.


13Characteristics and mutation analysis of Phpositive leukemia patients with T315I

mutation receiving tyrosine kinase inhibitors. OncoTargets and Therapy.2017-09.10

:4731-4738.


14A case report and literature review of primary resistant Hodgkin lymphoma: a

response to anti-PD-1 after failure of autologous stem cell transplantation and

brentuximab vedotin. OncoTargets and therapy.2016-09.9: 5781.


15Primary Philadelphia chromosome positive acute myeloid leukemia: A case repor

.Medicine (Baltimore).2018-11.97(44):e12949.


16Composite primary breast diffuse large Bcell lymphoma and T lymphoblastic

leukemia/lymphoma: report of a case and review of literature. Int J Clin Exp Pathol.

2015-08.8-8-9629.


17An Effective Gene Selection Method for Cancer Subtype Classification Based on

Predatory Search Genetic Algorithm and Support Vector Machine. Journal of Computational and Theoretical Nanoscience. Journal of Computational and Theoretical Nanoscience.

2015-09.1(11);1-7.


18Splenic diffuse red pulp small B-cell lymphoma in an Asian female patient with review of literature. Int J Clin Exp Med .2018-01.9(3):3993-3998.


19Acute lymphoblastic leukemia in a patient with IgG4-related disease. Pharmazi

Pharmazie.2018-07.73(7):418-421.


20The association between expression of hypoxia inducible factor-1a and multi-drug resistance of acute myeloid leukemia Translational Cancer Research.2017-02.6(1):

198-205.


21The polymorphism of JAK2 rs56118985 may be a predictive marker of the treatment

responses of acute myeloid leukemia patients .Translational Cancer Research.2017-05.10:4731-4738.


22Secondary Epstein-Barr virus-associated angioimmunoblastic Tcell lymphoma in a

patient with diffuse large B-cell lymphoma: report of a case and review of literature.

Translational Cancer Research.2017-02.10(1):1693-1708.

承担科研项目[项目负责人]

1、十三五江苏省科教强卫医学领军人才与创新团队

项目来源:江苏省卫计委;项目起止时间:2017-012021-12

项目主持人:陈兵;经费金额:300


2CARgy3-T细胞治疗B细胞淋巴瘤临床前研究

项目来源:江苏省科技计划项目临床前沿;项目起止时间:2017-092020-12

项目主持人:陈兵;经费金额:200


获奖情况

1、强心甾类固醇及纳米技术治疗淋巴系统肿瘤的基础及临床转化研究

南京市科技进步奖,三等奖;评奖单位:南京市人民政府;获奖时间:2017-12


2MYC+BCL2调整的国际预后指数在弥漫大B细胞淋巴瘤中的应用

江苏省医学新技术引进奖,二等奖;评奖单位:江苏省卫计委;获奖时间:2017-12


3、强心甾类固醇及纳米技术治疗淋巴系统肿瘤的基础及临床转化研究

江苏肿瘤医学科学技术奖,二等奖;评奖单位:江苏省抗癌协会;获奖时间:2017-12


4、自体造血干细胞移植治疗自身免疫病的临床应用

江苏省医学新技术引进奖,一等奖;评奖单位:江苏生卫生厅;获奖时间:2013-6


5、自体造血干细胞移植治疗自身免疫病的基础研究及临床应用

江苏省科学技术进步奖,三等奖;评奖单位:江苏省人民政府;获奖时间:2012-2


6、自体造血干细胞移植治疗自身免疫病的基础研究及临床应用

南京市科学技术进步奖,三等奖;评奖单位:南京市人民政府;获奖时间:2011-1